CDMO invests millions to expand API manufacturing capabilities

Piramal Pharma Solutions (PPS), a contract development and manufacturing organisation (CDMO), is investing $55 million across its sites in North America and Asia to expand its API manufacturing capabilities and capacities.

The investment will be use in part to fund the development of new multi-purpose plants with more than 270 kL of total capacity. These plants will be used to support the company’s current pipeline of around 80 late-stage clinical programmes.

Additionally, the investment will be used to expand the company’s potency footprint in the Riverview site (Michigan) and also to add GMP kilo labs and a pilot plant to increase the Indian early development capabilities located in Ennore.

European customers will benefit from an investment into the Morpeth facility in the UK, where PPS will add early development capabilities. All global API sites will also gain expanded support functions through the investment.

Vivek Sharma, CEO — Piramal Pharma Solutions commented: “We are committed towards investing in our customers’ future needs. With these investments, we can now support the commercialisation of our pipeline of over 80 programmes that are at Phase II or beyond, while allowing us additional capacity for future partnerships. There has been significant customer interest in our ‘integrated’ offerings, and we are pleased to have over 60 integrated programmes at PPS across all phases of drug development.”